Finerenone in Hypertensive Non-Diabetic Chronic Kidney Disease: Evidence from the FIND-CKD Subgroup Analysis
Highlight
- Finerenone slows estimated glomerular filtration rate (eGFR) decline in hypertensive non-diabetic chronic kidney disease (CKD).
- It significantly reduces the composite kidney-cardiovascular outcome including kidney failure and cardiovascular events.
- The benefits occur regardless of baseline systolic blood pressure levels.
- Finerenone’s safety is acceptable, with hyperkalaemia being the primary adverse event, rarely leading to treatment discontinuation.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.